IQVIA™ Real-World Insights Bibliography

Clinical and Economic Burden of Mild-to-Moderate Atopic Dermatitis in the UK: A Propensity-Score-Matched Case-Control Study
Author(s): Farah Toron 1, Maureen P Neary 2, Timothy W Smith 3, David Gruben 4, William Romero 5, Amy Cha 3, Keyur Patel 1, Simona Z Vasileva 6, Mahreen Ameen 7
Affiliations(s): 1Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. 2Inflammation & Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA. 3Inflammation & Immunology, Pfizer Inc, New York, New York, USA. 4Global Biometrics and Data Management (Statistics), Pfizer Inc, Groton, Connecticut, USA. 5Inflammation & Immunology, Pfizer Ltd, Surrey, UK. 6Health Economics and Outcomes Research, Real World Solutions, IQVIA, 210 Pentonville Road, London, N1 9JY, UK. simona.vasileva@iqvia.com. 7Royal Free London National Health Services Foundation Trust, London, UK.
Publication(s):  PMID: 33846907 PMCID: PMC8163940 DOI: 10.1007/s13555-021-00519-7
Document Type(s): Article,
Countries: UK,
Click here for the abstract
C:
Y:
Dermatology, Drug Utlization Study, Methodology,
2021
  L:
A:
English
direct to patient research, direct-to-patient research, Economic evaluation, Population Based Study, Retrospective database analysis,
  Add to report
 
 
Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden
Author(s): Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5
Affiliations(s): 1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA
Publication(s):  ECTRIMS 2021, Digital, 13-15 October 2021
Document Type(s): Abstract,
Countries: Finland, Sweden,
Click here for the abstract
C:
Y:
Drug Utlization Study, Neurological disorders,
2021
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis,
  Add to report
 
 
Interferon beta Exposure in the 2nd and 3rd Trimester of Pregnancy - a Register-based Drug Utilisation Study in Finland and Sweden
Author(s): Meritxell Sabidó1, Kiliana Suzart-Woischnik2, Nydjie Grimes3, Lisa M Prach4, Liwei Zhao5, Katja M Hakkarainen5
Affiliations(s): 1Merck Healthcare KGaA; 2Bayer AG; 3Biogen Netherlands B.V.; 4Novartis Pharma AG; 5Global Database Studies, IQVIA
Publication(s):  ECTRIMS 2021, Digital, 13-15 October 2021
Document Type(s): Poster,
Countries: Finland, Sweden,
Click here for the abstract
C:
Y:
Drug Utlization Study, Neurological disorders,
2021
  L:
A:
English
Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Population Based Study, Retrospective database analysis,
  Add to report
 
 
High clinician- and patient-reported satisfaction with individualized onabotulinumtoxinA treatment for spasticity across several etiologies from the ASPIRE study
Author(s): Gerard E.Franciscoa; Daniel S.Bandari; Ganesh Bavikattec; Wolfgang H.Jost; Emily McCusker; Joan Largent; Alekse Zuzek; Alberto Esquenazi
Affiliations(s): a The University of Texas Health Science Center McGovern Medical School and TIRR Memorial Hermann, Houston, TX, USA b Multiple Sclerosis Center of California & Research Group, Newport Beach, CA, USA c The Walton Centre, Liverpool, UK d University of Freiburg, Department of Neurology, Freiburg im Breisgau, Germany e Parkinson-Klinik Ortenau, Wolfach, Germany f Allergan, an AbbVie Company, Irvine, CA, USA g IQVIA Real-World Evidence Solutions, Cambridge, MA, USA h MossRehab Gait and Motion Analysis Laboratory, Elkins Park, PA, USA
Publication(s):  PM R . 2020 Jan 17. doi: 10.1002/pmrj.12328.
PMID: 31953896 DOI: 10.1002/pmrj.12328
Document Type(s): Article,
Countries: Asia Pacific, Europe, USA,
Click here for the abstract
C:
Y:
Drug Utlization Study, Medication compliance,
2020
  L:
A:
English
Methodology, Observational study,
  Add to report
 
 
A systematic literature review of the disease and economic burden of multidrug resistance gram negative infections (MRGN) in Japan
Author(s): T Hara 1, H Ikeoka 1, Adeeb Tawseef 2, Ryo Mitsuo 2 (rwesheorj 2)
Affiliations(s): 1) Shionogi & Co., Ltd., Osaka, Japan 2) IQVIA Solutions Japan KK, Tokyo, Japan
Publication(s):  ISPOR Asia Pacific 2020 Conference
Document Type(s): Abstract,
Countries: Japan,
Click here for the abstract
C:
Y:
Drug Utlization Study,
2020
  L:
A:
English
Burden of illness, Literature Review,
  Add to report
 
 
Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions
Author(s): Kristin M Sheffield , Nancy A Dreyer , James F Murray, Douglas E Faries & Megan N Klopchin
Affiliations(s): 1Global Patient Outcomes & Real World Evidence, Eli Lilly & Company, Indianapolis, IN 46225, USA 2IQVIA Real-World & Analytic Solutions, Cambridge, MA 02139, USA 3Real World Analytics, Eli Lilly & Company, Indianapolis, IN 46225, USA
Publication(s):  Published Online:11 Sep 2020https://doi.org/10.2217/cer-2020-0161
Document Type(s): Article,
Countries: USA,
Click here for the abstract
C:
Y:
Drug safety, Drug Utlization Study, Guidelines, Methodology, Public Health,
2020
  L:
A:
English
Methodology, Observational study, Population Based Study,
  Add to report
 
 
Patrones de tratamiento biológico en pacientes con enfermedades articulares inflamatorias. Estudio retrospectivo de 4 años de seguimiento
Author(s): Juan D. Cañete1, Antonio Naranjo2, Javier Calvo3, Carmen Ordás4, Belén Aragón5, Gonzalo Nocea5, Montse Roset6, Antonio Fernández-Nebro7
Affiliations(s): 1 Servicio de Reumatología, Hospital Clínic e IDIBAPS, Barcelona, España 2 Departamento de Reumatología, Hospital Dr. Negrín, Universidad de las Palmas de Gran Canaria, Las Palmas de Gran Canaria, España 3 Departamento de Reumatología, Hospital General Universitario de Valencia, Valencia, España 4 Departamento de Reumatología, Hospital de Cabueñes, Gijón, España 5 Departamento de Health Economics and Outcomes Research, MSD, Madrid, España 6 Departamento de Health Economics and Outcomes Research, IQVIA, Barcelona, España 7 Departamento de Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, España
Publication(s):  Reumatología Clínica, 2019. DOI: 10.1016
Document Type(s): Article,
Countries: Spain,
Click here for the abstract
C:
Y:
Drug Utlization Study,
2019
  L:
A:
Spanish
Clinical setting: hospital, Observational study,
  Add to report
 
 
Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe
Author(s): Fife D, Waller J, Kaplan S, Hu P, Phillips S, Oliveria SA, Richarz U
Affiliations(s): Fife: Janssen Research and Development, LLC Waller: Adephi Real World Kaplan: Teva Pharmaceutical Indusries Ltd. Hu: Janssen Global Services Phillips: IQVIA Oliveria, IQVIA Richarz: Janssen Research and Development, LLC
Publication(s):  Clin Drug Investig (2019). https://doi.org/10.1007/s40261-019-00831-3
Document Type(s): Article,
Countries: Belgium, France, Germany, Spain, UK,
Click here for the abstract
C:
Y:
Drug safety, Drug Utlization Study,
2019
  L:
A:
English
Population Based Study, Retrospective database analysis,
  Add to report
 
 
A population-based analysis of anti-diabetic medications in four Canadian provinces: secular trends and prescribing patterns
Author(s): Secrest MH, Azoulay L, Dahl M, Clemens KK, Durand M, Hu N, Targownik L, Turin TC, Dormuth CR, and Filion KB
Affiliations(s): IQVIA, Cambridge, MA
Publication(s):  Pharmacoepidemiology & Drug Safety (in press)
Document Type(s): Article, In press/to be published,
Countries: Canada,
C:
Y:
Diabetes, Drug Utlization Study,
2019
  L:
A:
English
Epidemiological study, Observational study, Retrospective cohort analysis, Retrospective database analysis,
  Add to report
 
 
Determining Real-World Data?s Fitness for Use and the Role of Reliability
Author(s): Nirosha Mahendraratnam Christina Silcox Kerra Mercon Adam Kroetsch Morgan Romine Nicholas Harrison Adam Aten Rachel Sherman Gregory Daniel* Mark McClellan
Affiliations(s): The Robert J. Margolis, MD, Center for Health Policy at Duke University is directed by Mark McClellan, MD, PhD, and brings together expertise from the Washington, DC, policy community, Duke University, and Duke Health to address the most pressing issues in health policy. The mission of Duke-Margolis is to improve health and the value of health care through practical, innovative, and evidence-based policy solutions. Duke-Margolis catalyzes Duke University?s leading capabilities, including interdisciplinary academic research and capacity for education and engagement, to inform policy making and implementation for better health and health care. For more information, visit healthpolicy.duke.edu.
Publication(s):  https://healthpolicy.duke.edu/sites/default/files/atoms/files/_determining_real-world_datas_fitness_for_use_and_the_role_of_reliability.pdf
Document Type(s): Health authorities guidelines/assessment report, Report,
Countries: 
Click here for the abstract
C:
Y:
Drug Utlization Study, Health policy,
2019
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
 1 of 4 Next Page Last Page